

BioSpect

the business of Bio

24 years of leveraging the business of Bio
www.biospectrumindia.com

Aurobindo Pharma receives a hike of 29% in Q2FY18, side-lines estimations

10 November 2017 | News

Aurobindo Pharma receives a hike of 29% in Q2FY18, side-lines estimations Aurobindo Pharma consolidated revenue for the quarter came in at Rs 4435.9 crore, registering 17.5 per cent yoy increase.



Aurobindo Pharma's Q2FY18 consolidated results for the quarter registered a beat on street estimates. Revenue for the quarter came in 4.5 per cent higher than the estimated figure of Rs 4245 crore. EBITDA for the quarter came in 4 per cent higher than the estimated figure of Rs 1074 crore. And lastly, net profit for the quarter came in 12.3 per cent higher than the estimated figure of Rs 695.7 crore.

Aurobindo Pharma consolidated revenue for the quarter came in at Rs 4435.9 crore, registering 17.5 per cent yoy increase.

EBITDA for the quarter rose by 20.2 per cent yoy to Rs 1116.9 crore with a corresponding margin expansion of 57 bps. EBITDA margin for the quarter stood at 25.2 per cent.

The PAT for the quarter came in at Rs 781.2 crore, yoy increase of 29 per cent. This was due to decline in effective tax rate to 20 per cent in Q2FY18 vs 27 per cent in corresponding quarter last year.

The board of directors has approved an interim dividend of Rs 1.5 per share for the face value of Rs 1 each.